Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP388B in Advanced Solid Tumors
NCT07730021Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2026
- Primary completion
- Feb 2030
- Countries
- 2
01
Overview
Phase 2, open-label trial of ASP388B in solid tumor, head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 3 more (7 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities up to 21 days, Treatment-Emergent Adverse Events up to 45 months and 5 more. Started Sep 2026; status: recruiting.
02
Drugs
ASP388B
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)prostate cancer (PCa)non-small cell lung cancer, squamous cell carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT07730021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730021.